These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7266742)

  • 1. Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit.
    Mann JJ; Stanley M; Neophytides A; de Leon MJ; Ferris SH; Gershon S
    Neurobiol Aging; 1981; 2(1):57-60. PubMed ID: 7266742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.
    Mann JJ; Stanley M; Kaplan RD; Sweeney J; Neophytides A
    J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):905-10. PubMed ID: 6644314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.
    Palmer AM; Sims NR; Bowen DM; Neary D; Palo J; Wikstrom J; Davison AN
    J Neurol Neurosurg Psychiatry; 1984 May; 47(5):481-4. PubMed ID: 6204017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls.
    Oreland L; Wiberg A; Asberg M; Träskman L; Sjöstrand L; Thorén P; Bertilsson L; Tybring G
    Psychiatry Res; 1981 Feb; 4(1):21-9. PubMed ID: 6164071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
    Gibson CJ; Logue M; Growdon JH
    Arch Neurol; 1985 May; 42(5):489-92. PubMed ID: 2581531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychological test performance and CSF levels of monoamine metabolites in healthy volunteers and patients with Alzheimer's dementia.
    Nybäck H; Nyman H; Schalling D
    Acta Psychiatr Scand; 1987 Dec; 76(6):648-56. PubMed ID: 2450445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin levels in CSF of Alzheimer patients: correlations with monoamine metabolites and neuropsychological test performance.
    Jolkkonen J; Helkala EL; Kutvonen R; Lehtinen M; Riekkinen PJ
    Psychoneuroendocrinology; 1989; 14(1-2):89-95. PubMed ID: 2471986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia.
    Corona GL; Cucchi ML; Frattini P; Santagostino G; Schinelli S; Romani A; Pola A; Zerbi F; Savoldi F
    Eur Arch Psychiatry Neurol Sci; 1989; 239(2):79-86. PubMed ID: 2478368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher cerebrospinal fluid MHPG in subjects with dementia of the Alzheimer type. Relationship with cognitive dysfunction.
    Sheline YI; Miller K; Bardgett ME; Csernansky JG
    Am J Geriatr Psychiatry; 1998; 6(2):155-61. PubMed ID: 9581211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine metabolites in the CSF of epileptic patients.
    Laxer KD; Sourkes TL; Fang TY; Young SN; Gauthier SG; Missala K
    Neurology; 1979 Aug; 29(8):1157-61. PubMed ID: 37460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF monoamine metabolites in old age dementias.
    Parnetti L; Gaiti A; Reboldi GP; Santucci C; Mecocci P; Brunetti M; Cadini D; Senin U
    Mol Chem Neuropathol; 1992; 16(1-2):143-57. PubMed ID: 1381590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia.
    Bråne G; Gottfries CG; Blennow K; Karlsson I; Lekman A; Parnetti L; Svennerholm L; Wallin A
    Alzheimer Dis Assoc Disord; 1989; 3(3):148-56. PubMed ID: 2477044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective attention in Alzheimer's disease: CSF correlates of behavioral impairments.
    Freed DM; Corkin S; Growdon JH; Nissen MJ
    Neuropsychologia; 1988; 26(6):895-902. PubMed ID: 2461537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggression in humans correlates with cerebrospinal fluid amine metabolites.
    Brown GL; Goodwin FK; Ballenger JC; Goyer PF; Major LF
    Psychiatry Res; 1979 Oct; 1(2):131-9. PubMed ID: 95232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine metabolite levels in cerebrospinal fluid and brain atrophy in lobotomized schizophrenic patients.
    Rimón R; Roos BE; Kampman R; Hyyppä S; Ranta P; Myllylä V
    Ann Clin Res; 1979 Feb; 11(1):25-9. PubMed ID: 453776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid concentration of biogenic amine metabolites in idiopathic apnea of prematurity.
    Bhat AM; Scanlon JW; Lavenstein B; Chuang L; Karoum F
    Biol Neonate; 1983; 43(1-2):16-22. PubMed ID: 6850011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?
    Scheinin M
    Med Biol; 1985; 63(1):1-17. PubMed ID: 2582215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF monoamine metabolites in schizophrenic patients.
    Gattaz WF; Waldmeier P; Beckmann H
    Acta Psychiatr Scand; 1982 Nov; 66(5):350-60. PubMed ID: 6184954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine metabolites in cerebrospinal fluid in multiple sclerosis.
    Davidson D; Pullar IA; Mawdsley C; Kinloch N; Yates CM
    J Neurol Neurosurg Psychiatry; 1977 Aug; 40(8):741-5. PubMed ID: 925693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amine metabolites in ventricular cerebrospinal fluid in coma.
    Yates CM; Tsementzis SA; Wilson H
    J Neurol Neurosurg Psychiatry; 1979 Oct; 42(10):887-91. PubMed ID: 512664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.